An Open-Label, Proof of Consent Study of Vorinostat for the Treatment of Mdoerate-to-Severe Crohn s Disease and Maintenance Therapy With Ustekinumab
Abroad (travel likely)RecruitingPHASE1, PHASE2
Conditions
Crohn's Disease
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Contact: Study coordinator (For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR) · prpl@cc.nih.gov · 800-411-1222
Study leads
Ivan J Fuss, M.D.
Principal Investigator
National Institute of Allergy and Infectious Diseases (NIAID)